Ascelia Pharma’s auditor is appointed by the annual general meeting for the period until the end of the next annual general meeting. The auditor examines the annual report and accounts as well as the management performed by the board of directors and the CEO. Following each financial year, the auditor shall submit an audit report to the annual general meeting. The auditor reports its observations from the audit and its assessment of Ascelia Pharma’s internal control to the board of directors.

At the Annual General Meeting held on 6 May 2020, ÖhrlingsPricewaterhouse Coopers AB was re-elected as Ascelia Pharma’s auditor for the time period up until the next annual shareholders’ meeting. ÖhrlingsPricewaterhouse Coopers AB is represented by Carl Fogelberg who holds the main responsibility for the audit of Ascelia Pharma.

About us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway.

Headquarter is in Malmö, Sweden, and the company’s shares are listed on Nasdaq Stockholm (ticker: ACE)